Akero Therapeutics, INC

Akero Therapeutics, Inc. has completed its merger with Novo Nordisk A/S, becoming a wholly-owned subsidiary and delisting from Nasdaq.

Akero Therapeutics stockholders have approved the company's acquisition by Novo Nordisk A/S, with early termination of the HSR waiting period also granted.

Akero Therapeutics has agreed to be acquired by Novo Nordisk for up to $5.2 billion in cash, including a contingent value right tied to efruxifermin's FDA approval.

Akero Therapeutics, Inc. has completed the voluntary early prepayment of its $37.6 million loan agreement with Hercules Capital, Inc., terminating the facility ahead of schedule.

Akero Therapeutics announced its second quarter 2025 financial results, highlighting significant progress in its EFX clinical program for MASH, including key data publications and presentations.

Akero Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders held on June 3, 2025, where shareholders approved the election of two Class III directors, ratified Deloitte & Touche LLP as auditors, and endorsed executive compensation.

Akero Therapeutics reports Q3 2025 results, highlighting progress in its Phase 3 SYNCHRONY program for MASH and the pending acquisition by Novo Nordisk for $54.00 cash plus a $6.00 CVR per share.

Akero Therapeutics reports increased net losses in Q2 2025 as it advances its lead MASH drug candidate, EFX, through a global Phase 3 clinical program.

Akero Therapeutics reports a net loss for Q1 2025 and discusses the progress of its Phase 3 SYNCHRONY program for efruxifermin (EFX).

Akero Therapeutics reports increased R&D spending in Q3 2024 as it advances its Phase 3 MASH program, while maintaining a strong cash position.

Akero Therapeutics, a clinical-stage biotech company, released its Q2 2024 financial results, highlighting increased R&D spending and ongoing clinical trial progress for its lead drug candidate, EFX.

Akero Therapeutics reports a net loss of $53.3 million for Q1 2024, alongside a significant increase in cash reserves following a successful follow-on public offering.

Akero Therapeutics' 10-K filing reveals ongoing financial losses as the company progresses with clinical trials for Efruxifermin (EFX), a potential treatment for Metabolic dysfunction-associated steatohepatitis (MASH).

Akero Therapeutics, a clinical-stage biotech company, released its 2023 financial results and provided an update on its lead drug candidate, efruxifermin (EFX), for treating metabolic dysfunction-associated steatohepatitis (MASH).

Tomas J. Heyman, a director at Akero Therapeutics, Inc., disposed of all his common stock and stock options following the company's merger with Novo Nordisk A/S.

Akero Therapeutics director Yuan Xu disposed of all beneficial ownership in the company following its acquisition by Novo Nordisk.

Akero Therapeutics President and CEO, Andrew Cheng, converted all his common stock, RSUs, and stock options into cash and contingent value rights following the company's merger with Novo Nordisk's subsidiary.

Akero Therapeutics director Seth Loring Harrison disposed of all common stock and options following the company's acquisition by Novo Nordisk, receiving cash and contingent value rights.

Akero Therapeutics Director Graham G. Walmsley disposed of common stock, restricted stock units, and stock options following the company's merger with Novo Nordisk A/S, receiving cash and contingent value rights.

Akero Therapeutics Director Judy Chou converted her restricted stock units and stock options into cash and contingent value rights following the merger with Novo Nordisk.

Akero Therapeutics filed a supplement to its definitive proxy statement for the upcoming special meeting, providing additional disclosures regarding its proposed merger with Novo Nordisk and addressing two stockholder lawsuits.

Akero Therapeutics stockholders are invited to a special meeting on December 2, 2025, to vote on the proposed acquisition by Novo Nordisk A/S for $54.00 cash per share plus a $6.00 contingent value right.

Novo Nordisk has entered into an agreement to acquire Akero Therapeutics for $54.00 per share in cash plus a Contingent Value Right of $6.00, totaling an equity value of approximately $5.2 billion if milestones are met.

Akero Therapeutics has agreed to be acquired by Novo Nordisk for up to $5.2 billion in cash, including a contingent value right tied to regulatory approval of efruxifermin.

Akero Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 3, 2025, featuring proposals for director elections, auditor ratification, and executive compensation approval.

Akero Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 7, 2024, to vote on key proposals, including the election of directors, ratification of the accounting firm, executive compensation, and an amendment to limit officer liability.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting a reduced beneficial ownership of 4.1% in Akero Therapeutics, Inc.

RTW Investments and Roderick Wong have fully divested their beneficial ownership in Akero Therapeutics, Inc., now holding 0.0% of common stock.

Deep Track Capital and its affiliates have reported a 0% beneficial ownership in Akero Therapeutics, Inc., indicating a full divestment or reduction below the reporting threshold.

Wellington Management Group and its affiliates have reported a 0.0% beneficial ownership in Akero Therapeutics, Inc. common stock, indicating a full divestment.

T. Rowe Price Associates, Inc. reported a 4.8% beneficial ownership in Akero Therapeutics Inc., indicating a position below the 5% threshold.

Janus Henderson Group plc has increased its beneficial ownership in Akero Therapeutics, Inc. to 7.9% of ordinary shares, as disclosed in an amended Schedule 13G filing.